SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
SEC Accession No. 0001193125-24-018222
Filing Date
2024-01-29
Accepted
2024-01-29 16:52:14
Documents
8
Period of Report
2024-01-29

Document Format Files

Seq Description Document Type Size
1 PREM14A d734477dprem14a.htm PREM14A 1572290
2 EX-FILING FEES d734477dexfilingfees.htm EX-FILING FEES 18173
3 GRAPHIC g734477g06k01.jpg GRAPHIC 219666
4 GRAPHIC g734477g07k02.jpg GRAPHIC 259530
5 GRAPHIC g734477g09t03.jpg GRAPHIC 25958
6 GRAPHIC g734477g59k18.jpg GRAPHIC 32199
7 GRAPHIC g734477g76c08.jpg GRAPHIC 63177
8 GRAPHIC g734477g85d98.jpg GRAPHIC 53488
  Complete submission text file 0001193125-24-018222.txt   2486763
Mailing Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 (650) 443-7400
Harpoon Therapeutics, Inc. (Filer) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREM14A | Act: 34 | File No.: 001-38800 | Film No.: 24574363
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)